As an oral targeted drug, the standard dose of Pirtobrutinib is 200mg once daily, but special attention should be paid to its safety issues such as liver toxicity and infection risk. Patients should fully understand the precautions of Pirtobrutinib.

Precautions for Pirtobrutinib

Risk of infection

Serious and fatal infections (including bacterial, viral or fungal infections and opportunistic infections) may occur during use. Signs of infection should be closely monitored, anti-infection treatment should be given if necessary, and preventive measures (such as vaccination and antimicrobial prevention) should be considered.

Risk of bleeding

Serious and fatal bleeding events (including central nervous system bleeding and gastrointestinal bleeding) have been reported. Before using Pirtobrutinib, the patient should be evaluated for bleeding risk factors and bleeding should be closely monitored during use.

Hematological abnormalities

Pirtobrutinib may cause a significant decrease in neutrophils, platelets and red blood cells. It is recommended to monitor the complete blood count regularly and adjust the dose or interrupt treatment according to the situation.

Arrhythmia

Including abnormal heart rhythms such as atrial fibrillation or atrial flutter, especially in patients with underlying cardiovascular diseases. If symptoms such as palpitations, dizziness, and syncope occur, you should seek medical attention in time.

Second primary malignant tumors

There are reports that patients may develop skin cancer and other solid tumors during use. Patients should be reminded to pay attention to sun protection and monitor regularly.

Hepatotoxicity

It is necessary to monitor liver function indicators (such as bilirubin and transaminase). If abnormalities occur, adjustments or discontinuation of the drug should be considered.

Embryo-fetal toxicity

It has been proven that embryotoxicity exists in animal experiments, so women of childbearing age should take effective contraceptive measures when using it.